World Journal of Cardiology · 2016 · 18 citations · 33 references
MedicineDermatologyImmunologyAutoimmunityImmunopathologyInflammationCytokine BiologyInflammatory BiomarkersInflammatory Skin DiseasesPlatelet ActivationPlatelet FunctionPlatelet PhysiologyFlow Cytometric Platelet AnalysisFlow Cytometry ImmunophenotypingMicroparticlesPlatelet Activation AssaysPlatelet-to-lymphocyte RatioPsoriasis ImmunopathologyPsoriatic DiseaseSystemic Inflammation Markers
AIM: To evaluate platelet activation markers in psoriasis patients, compared to controls, and investigate their association with the inflammatory burden of psoriasis. METHODS: ., platelet-monocyte complexes (PMC), platelet-neutrophil complexes (PNC) and platelet-lymphocyte complexes, and concentrations of platelet-derived microparticles (PMPs) using flow cytometry. Both larger-size (0.5-0.9 μm) and smaller-size (< 0.5 μm) PMPs were determined. Serum interleukin (IL)-12 and IL-17 levels were also measured by enzyme-linked immunosorbent assay. The severity of psoriasis was evaluated by the Psoriasis Area Severity Index (PASI). RESULTS: 0.01). CONCLUSION: PMPs, known to be predictive of cardiovascular outcomes, are increased in psoriasis patients, and associated with high inflammatory disease burden. Enhanced platelet activation may be the missing link leading to cardiovascular events in psoriatic patients.
33
Risk of Myocardial Infarction in Patients With Psoriasis
Joel M. Gelfand, Andrea L. Neimann, Daniel B. Shin et al. · JAMA · 2006 · 1.9K citations
Medicine, Cardiology, Dermatology +15
Prevalence and Treatment of Psoriasis in the United Kingdom
Joel M. Gelfand, Rachel Weinstein, Steven B. Porter et al. · Archives of Dermatology · 2005 · 598 citations
Alan D. Michelson, M.R. BARNARD, Herbert B. Hechtman et al. · Proceedings of the National Academy of Sciences · 1996 · 557 citations